Stock APGE APOGEE THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Analyst Reco. Apogee Therapeutics, Inc.

Equities

APGE

US03770N1019

Market Closed - Nasdaq
Other stock markets
 04:00:03 2024-05-31 pm EDT 		5-day change 1st Jan Change
45.64 USD -1.55% Intraday chart for Apogee Therapeutics, Inc. -4.98% +63.35%
May. 28 Apogee Therapeutics, Inc. Appoints Lisa Bollinger to Its Board of Directors CI
May. 15 Apogee Announces Dosing of First Patient in Phase 2 Atopic Dermatitis Trial of APG777, a Novel Subcutaneous Half-life Extended Anti-IL-13 Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory Diseases CI

Analyst Reco.

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
BofA Securities Starts Coverage on Apogee Therapeutics With Buy Rating, $80 Price Target
MT
Jefferies Adjusts Price Target on Apogee Therapeutics to $75 From $37, Maintains Buy Rating
MT
Wedbush Raises Apogee Therapeutics' PT to $87 From $40 After Reporting Initial Safety, PK Results From Phase 1 Trial of APG777; Maintains Outperform Rating
MT
Guggenheim Adjusts Apogee Therapeutics' Price Target to $44 From $29, Maintains Buy Rating
MT
BTIG Initiates Apogee Therapeutics With Buy Rating, Price Target is $43
MT
TD Cowen Initiates Apogee Therapeutics With Outperform Rating
MT
Stifel Initiates Apogee Therapeutics With Buy Rating, $34 Price Target
MT
Jefferies Initiates Apogee Therapeutics With Buy Rating, $29 Price Target
MT
Guggenheim Starts Apogee Therapeutics With Buy Rating, $29 Price Target
MT
Wedbush Initiates Apogee Therapeutics at Outperform With $40 Price Target
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. APGE Stock
  4. News Apogee Therapeutics, Inc.
  5. Analyst Reco.